MedTrace Logo

The Effect of Lixisenatide on the Effect of Pituitary Hormones

NCT05804513 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-06-12

No results posted yet for this study

Summary

The current study has two aims:

1. to test the hypothesis that a single dose of lixisenatide can be used as a growth hormone stimulation test;
2. to test if the growth hormone-stimulating effect is mediated by changes in blood glucose.

The secondary objective of the study is to monitor the effect of lixisenatide on other pituitary hormones and physiological parameters (blood glucose, blood pressure, heart rate, nausea).

Conditions

Interventions

DRUG

Placebo

s/c injection

DRUG

Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector

s/c injection

Sponsors & Collaborators

  • Tartu University Hospital

    collaborator OTHER

  • University of Tartu

    lead OTHER

Principal Investigators

  • Vallo Volke, MD, PhD · University of Tartu, Tartu University Hosptial

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-04-17
Primary Completion
2023-10-31
Completion
2023-12-31

Countries

  • Estonia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05804513 on ClinicalTrials.gov